Osimertinib is a 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), proven effective as 1st line treatment in patients with advanced non-small cell lung cancer (NSCLC) harboring the EGFR mutation.[1] As an EGFR-TKI, osimertinib has reported milder toxicities compared with the other EGFR-TKIs such as gefitinib, erlotinib, and afatinib. Here, EGFR is linked to non-small cell lung carcinoma.